Actively Recruiting
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
Led by Peking University Shenzhen Hospital · Updated on 2026-01-29
20
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
Sponsors
P
Peking University Shenzhen Hospital
Lead Sponsor
S
Shenzhen People's Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This observational study aims to evaluate the real-world effectiveness and safety of iruplinalkib in patients with advanced ALK-positive lung adenocarcinoma who have progressed on or are intolerant to prior lorlatinib therapy. The results are expected to provide real-world evidence to inform clinical decision-making for this heavily pretreated patient population.
CONDITIONS
Official Title
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients aged 6518 years
- Histologically or cytologically confirmed advanced lung adenocarcinoma
- ALK rearrangement confirmed by validated test (e.g., NGS, IHC, FISH)
- Prior treatment with lorlatinib with documented disease progression or intolerance
- Started treatment with iruplinalkib in real-world clinical practice
- At least one evaluable lesion for response assessment
- Availability of key clinical data including baseline characteristics, treatment history, and follow-up outcomes
You will not qualify if you...
- Patients who have not received iruplinalkib or took less than one week before withdrawal for non-medical reasons
- Presence of active malignancy of other histological types (excluding treated basal cell carcinoma)
- Participation in another interventional clinical trial with investigational anti-tumor drugs concurrently
- Pregnant or breastfeeding women
- Missing critical medical records that prevent assessment of primary endpoints (e.g., unknown treatment start date, unknown prior therapy)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China, 518000
Actively Recruiting
Research Team
F
FEN WANG
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here